

---

### **Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial**

---

Correction to: *Nature Medicine* <https://doi.org/10.1038/s41591-022-02011-x>, published online 3 October 2022.

<https://doi.org/10.1038/s41591-023-02301-y>

Published online: 17 March 2023

**Jeremy Pettus<sup>1</sup>**, **Schafer C. Boeder<sup>2</sup>**, **Mark P. Christiansen**,  
**Douglas S. Denham**, **Timothy S. Bailey<sup>3</sup>**, **Halis K. Akturk<sup>4</sup>**, **Leslie J. Klaff**,  
**Julio Rosenstock**, **Mickie H. M. Cheng**, **Bruce W. Bode**, **Edgar D. Bautista**, **Ren Xu**,  
**Hai Yan**, **Dung Thai**, **Satish K. Garg** & **Samuel Klein**

In the version of this article initially published, the ClinicalTrials.gov registration number, NCT03117998, was missing from the Abstract. It has now been inserted in the HTML and PDF versions of the article.

© The Author(s), under exclusive licence to Springer Nature America, Inc. 2023